Two‐center Comparison of Commercial PCT Immunoassays
Procalcitonin is a biomarker for sepsis and can be a powerful tool for insights when combined with other findings from the patient’s medical history, physical examination and other assessments.
Based on PCT levels, clinicians in the intensive care unit, for example, can use procalcitonin to aid in the risk assessment for progression to severe sepsis and septic shock.
However, unresolved issues remain when it comes to procalcitonin and sepsis, including a lack of standardization in procalcitonin level measurement. To investigate this, a peer‐reviewed clinical study was designed to evaluate PCT test results and their comparability across ten fully automated commercial assays.
In this peer‐reviewed clinical study, the Access PCT immunoassay is shown to have strong correlation and method concordance to established methods at key clinical decision points, making it a valuable tool to aid clinicians in diagnosing progression to severe sepsis or septic shock.
Article Two‐center Comparison of Commercial PCT Immunoassays
In this study of fully automated procalcitonin immunoassays, Access PCT shows strong correlation and method concordance to the established method at key clinical decision points when used as an aid in diagnosing progression to severe sepsis or septic shock.
Complete the form below to download your copy of the article.
Never miss another insight
Subscribe to our Diagnostics Today newsletter to stay up to date on the latest news in clinical diagnostics.
Lippi G., Salvagno G.L. et al., Two‐centers comparison of 10 fully‐automated commercial procalcitonin (PCT) immunoassays. Clin Chem Lab Med 2019; doi: https://doi.org/10.1515/cclm‐2019‐0888.